Rare Immunology News

Advertisement

Spotlight On

Sjögren’s syndrome

Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva

Prevalence

7-10/100,000

23,170 - 35,945

Us Estimated

33,100 - 51,350

Europe estimated

Age of Onset

ICD-10

M35. 0

Inheritance

This condition does not appear to have a clear pattern of inheritance.

Rare View

Sjögren’s syndrome is a chronic autoimmune disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. The main symptoms are dry eyes and mouth, but other parts of the body may be affected as well, with many people reporting fatigue and joint and muscle pain. In addition, the disease can damage the lungs, kidneys, and nervous system. Sjögren’s syndrome predominantly affects women.†

5 Facts you should know

FACT

1

Autoimmune disease that affects the body's moisture-producing glands

FACT

2

The hallmark symptom of Sjögren syndrome is dry mouth and keratoconjunctivitis sicca

FACT

3

Other symptoms can include dry skin, vaginal dryness, a chronic cough, numbness in the arms and legs, feeling tired, muscle and joint pains, and thyroid problems

FACT

4

Sjögren's syndrome may be associated with other autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis

FACT

5

Those affected are also at an increased risk (15%) of lymphoma

Sjögren’s syndrome is also known as...

Sjögren’s syndrome is also known as:

SjS, SS 

What’s your Rare IQ?

Which famous female tennis player was diagnosed with Sjögren’s syndrome at age 31?

Common signs & symptoms

The most common symptoms are:

  • Dry eyes.Your eyes may burn or itch or feel like they have sand in them. Sometimes, the dryness causes blurry vision or sensitivity to bright light. You may get irritated, itchy eyelids due to inflammation.
  • Dry mouth.Your mouth may feel chalky, and you may have trouble swallowing, speaking, and tasting. You may develop more cavities and mouth infections.

In some cases, Sjögren’s syndrome affects other tissues and organs and has more widespread effects on the body. These other effects may cause:

Fatigue (feeling very tired)

Joint pain and muscle aches and weakness

Dry skin, nasal passages, and throat, and a dry cough

Skin rashes

Swelling of the glands around the face and neck

Trouble sleeping

Poor concentration and memory problems

Numbness, tingling, and weakness, especially in your arms and legs

Shortness of breath or trouble breathing

Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Current treatments

There is no cure for Sjögren’s syndrome, so treatment focuses on relieving symptoms and preventing complications. Treatments are different for each person and will depend on which parts of the body are affected.

Eye treatments:

Eye drops (artificial tears)

Some people need prescription eye drops that contain medications to suppress the immune system and reduce inflammation in the eye.

Eye ointments

Punctal occlusion

Small plugs placed in the tear duct in the corners of the eyes block drainage and keep tears in the eyes longer.

Mouth treatments:

Artificial saliva

Saliva production stimulators

Cevimeline (Evoxac)

Pilocarpine (Salagen)

Anti-fungal medications

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeA randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)Phase 3ActiveBiological: VAY736
Other: Placebo
More Info
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeThe purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.Phase 3ActiveDrug: Deucravacitinib
Other: Placebo
More Info
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityThis is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).Phase 2ActiveDrug: IMVT-1402
Drug: Placebo
More Info
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sThis is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.Phase 2ActiveBiological: Sibeprenlimab
Other: Placebo
More Info
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren SyndromeThis is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.Phase 2Not yet recruitingDrug: ESG206
Drug: Placebo
More Info
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren DiseaseBackground:

Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs. It can also cause dry mouth and eyes, fever, joint pain, rashes, and other symptoms. R...
Phase 2RecruitingDrug: TofacitinibMore Info
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's DiseaseA phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.Phase 1RecruitingDrug: CLN-978More Info
TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENESjögren's disease (SjD) is a chronic, immune-mediated, systemic inflammatory disease characterized mainly by involvement of the salivary and lacrimal glands, causing symptoms of sicca syndrome. The disease predominantly affects women (9:1 to 20:1), with a peak incidence between 40 and 60 years of ag...Phase 4RecruitingDevice: Fractional CO2 laser (vaginal)
Drug: Promestriene Vaginal
More Info
Fatigue in Sjögren's Syndrome: 3 Therapeutic StrategiesUnexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and feasible, but only to some extent. Hence, other therapeutic approaches, such a...N/ARecruitingDevice: Acupuncture (ACU)
Device: Transcutaneous Vagus Nerve Stimulation (tVNS)
Other: APA (adapted physical activity )
Device: Acupuncture (sham_ACU)
Device: Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS)
More Info
Evaluating a New Therapy for Dry Eye in Patients With Sjögren's SyndromeThis study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.Phase 4RecruitingDrug: TRYPTYR (Acoltremon ophthalmic solution 0.003%)More Info

Top Treatments in Research

AgentClass/MOADevelopment StatusCompanyCompany ContactClinical StudiesMore Information
Ianalumab (VAY736)Anti-BAFF-R monoclonal antibody — depletes B cells via antibody-dependent cellular cytotoxicity (ADCC) and blocks BAFF-R-mediated survival signalingPhase 3NovartisStudy Director / NovartisMore infohttps://clinicaltrials.gov/study/NCT05349214
DeucravacitinibSelective allosteric TYK2 (tyrosine kinase 2) inhibitor — suppresses type I interferon and IL-12/IL-23 signaling pathways; oral small moleculePhase 3Bristol-Myers SquibbStudy Director / Bristol-Myers SquibbMore infohttps://clinicaltrials.gov/study/NCT05946941
IMVT-1402Anti-FcRn (neonatal Fc receptor) monoclonal antibody — reduces pathogenic IgG autoantibodies by blocking Fc recycling; subcutaneous administrationPhase 2ImmunovantStudy Director / ImmunovantMore infohttps://clinicaltrials.gov/study/NCT06979531
SibeprenlimabAnti-APRIL (A proliferation-inducing ligand) monoclonal antibody — blocks B cell survival factor to reduce plasmablast and plasma cell activityPhase 2Otsuka PharmaceuticalStudy Director / OtsukaMore infohttps://clinicaltrials.gov/study/NCT06928142
ESG206Anti-BAFF-R monoclonal antibody — targets B cell activating factor receptor to selectively deplete autoreactive B cellsPhase 2Escugen BiotechnologyQing Zhou, PhDMore infohttps://clinicaltrials.gov/study/NCT07375524
TofacitinibJAK1/JAK3 inhibitor — suppresses pro-inflammatory cytokine signaling (IL-6, IFN-γ, IL-17); oral small molecule already approved in other autoimmune conditionsPhase 2NIDCR / NIHSasha D. NubyMore infohttps://clinicaltrials.gov/study/NCT07281456
CLN-978CD19 × CD3 bispecific T cell engager — redirects cytotoxic T cells to deplete CD19+ autoreactive B cells; subcutaneous administrationPhase 1Cullinan TherapeuticsAmy Gubits, MPHMore infohttps://clinicaltrials.gov/study/NCT07041099

† Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 https://rarediseases.info.nih.gov